Improve Health for Patient with Sexually Transmitted Infections (STIs)
- Pathogens causing reproductive tract infections have a high prevalence rate in the population, often presenting as asymptomatic infections with a high rate of co-infections. Delayed treatment can easily lead to infertility or adverse pregnancy outcomes.
- The molecular point-of-care diagnostic solutions of USTAR enhances the ability and timeliness of detecting infectious pathogens, assisting in early clinical diagnosis and intervention, thereby further improving maternal and infant health during pregnancy and the perinatal period. With its rapid and accurate results, non-invasive sampling, and on-demand testing, it supports clinical practices in achieving same-day diagnosis and treatment closure, improving the patient healthcare experience.
Highly Sensitive and Accurate:
Compared to antigen and antibody testing, nucleic acid testing offers higher sensitivity and specificity, making it the preferred detection method recommended in clinical guidelines.
Broad Pathogen Coverage:
Nucleic acid testing can detect Mycoplasma genitalium, which is not suitable for antigen testing.
Reduced Turn-around-time (TAT):
Results are available in 45 minutes, providing rapid decision-making support for clinical practice.
Flexible Combination Testing:
Options for single or dual-target testing allow clinicians to adapt to seasonal prevalence trends, reducing the healthcare burden.
On-Demand Testing:
Independent testing channels eliminate the need for batch processing and waiting.
Wide Range of Applications:
Deliver comprehensive STI solutions for both laboratory and decentralized settings.
